Trends in Rates of Myocardial Infarction among Patients with HIV

Publisher Website
Google Scholar
Abstract
The use of protease-inhibitor drugs is associated with increased levels of triglycerides, total cholesterol, and low-density lipoprotein cholesterol and with diabetic diathesis in patients infected with the human immunodeficiency virus (HIV).1 Because these metabolic problems can lead to cardiovascular disease, we examined data from the HIV Outpatient Study (HOPS), which involved a large cohort of HIV-infected outpatients followed at nine HIV clinics in seven U.S. cities: 3247 patients who had taken protease inhibitors for more than six months, and 2425 patients who had not taken protease inhibitors. These patients were followed for a total of 17,712 person-years of observation.